Printer Friendly

ALLEGHENY GENERAL HOSPITAL STUDY: CRYOSURGERY MAY BE EFFECTIVE TREATMENT FOR PROSTATE CANCER

 PITTSBURGH, Aug. 9 /PRNewswire/ -- A study co-authored by two Allegheny General Hospital (AGH) physicians and published in the current (Aug. 15, 1993) issue of the scientific journal CANCER suggests that a minimally invasive
surgical procedure known as Percutaneous Ultrasound- guided Prostate Cryosurgery may be an effective treatment for prostate cancer.
 Prostate cryosurgery uses supercooled liquid nitrogen to destroy the cancerous prostate. Study results show more than 80 percent of the patients had their localized prostate cancer eradicated.
 According to Gary M. Onik, M.D., an interventional radiologist at AGH and a professor in the Department of Neurosurgery at the Medical College of Pennsylvania (MCP), and Jeffrey K. Cohen, M.D., of AGH's Department of Urology and an assistant professor of surgery at MCP, prostate cryosurgery enables physicians to treat patients that heretofore have been untreatable through conventional surgery (radical prostatectomy) or radiation therapy, or where such treatments would have had unacceptable morbidity (side effects).
 Preliminary study results had been released -- in abstract form -- in December 1992 during the 78th Scientific Assembly and Annual Meeting of the Radiological Society of North America in Chicago.
 Prostate cancer is the second leading cause of cancer deaths in men. It affects about 132,000 people annually, or one in nine American males. About 34,000 men die of prostate cancer each year in the United States.
 -0- 8/9/93
 /EDITORS: Media wanting to interview Onik and Cohen should contact the media relations department at Allegheny General Hospital at 412-359-8600./
 /CONTACT: Colin McNickle of Allegheny General Hospital, 412-


359-8600/

CO: Allegheny General Hospital; Medical College of Pennsylvania ST: Pennsylvania IN: HEA SU:

CD-KC -- PG001 -- 0601 08/09/93 08:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 9, 1993
Words:277
Previous Article:SAFECARD TO REASSERT CLAIMS AGAINST PETER A. HALMOS
Next Article:WYETH-AYERST'S LODINE(R) 400MG RECEIVES FDA MARKET CLEARANCE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters